Status: Not yet recruiting
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
This study will evaluate the safety and efficacy of NALIRIFOX per NAPOLI-3 regimen as first-line chemotherapy for patients with advanced small intestine and appendiceal cancers. Female or male patients aged 18 years, or older, with histopathologically or cytologically confirmed advanced mucinous or non-mucinous appendix cancer or advanced small intestine cancer will be eligible for participation in the study.
Participants needed: 22
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: The Methodist Hospital Research InstituteUpdated: Jul 11, 2025Locations: 1
Eligibility criteria
Male or female ≥18 years of age. [+5]
Absolute neutrophil count ≤1500 cells/mm3 [+10]